Latin American association for the study of the liver practice guidelines on Diagnosis, management, and treatment of hepatitis C

Annals of Hepatology

Volumn 9, Issue SUPPL. 1, 2010, Pages 8-26

  Méndez Sánchez, Nahum ^a   Gadano, Adrian ^a   Soza, Alejandro ^a   de Mattos, Angelo Alves ^a   Claudio, Augusto Marroni ^a   Galoppo, Marcela ^a   Kershenobich, David ^a   Strauss, Edna ^a   Fassio, Eduardo ^a   Castañeda, Gilberto ^a   Valladares, Guillermo ^a   Moraes, Henrique Sergio Coelho ^a   Daruich, Jorge ^a   Garassini, Miguel ^a   Dávalos, Milagros ^a   Uribe, Misael ^a   Rodriguez Torres, Maribel ^a   Zapata, Rodrigo ^a   Arrese, Marco ^a   Sánchez Ávila, Francisco ^a   Dehesa, Margarita ^a   Padilla, Francisco Bosques ^a   de Almeida, Paulo Roberto Lerias ^a   Pessoa, Mario ^a   Torres Ibarra, Rocío ^a   Hevia, Francisco ^a   Contreras, Miguel ^a   Cheinquer, Hugo ^a   more..

^a Latin American Association for the Study of the Liver (ALEH)   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PROTEINASE INHIBITOR; RIBAVIRIN; RNA DIRECTED RNA POLYMERASE INHIBITOR; VIRUS ANTIBODY; VIRUS RNA; ANTIVIRUS AGENT;

ACUTE HEPATITIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; COMBINATION CHEMOTHERAPY; DECOMPENSATED LIVER CIRRHOSIS; DEPRESSION; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG INDICATION; DRUG MONITORING; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; EVIDENCE BASED MEDICINE; FATIGUE; FLU LIKE SYNDROME; GEOGRAPHIC DISTRIBUTION; GOLD STANDARD; HASHIMOTO DISEASE; HEMOLYTIC ANEMIA; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; INSULIN RESISTANCE; KIDNEY DISEASE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER TRANSPLANTATION; METABOLIC SYNDROME X; MIXED INFECTION; MONOTHERAPY; NATIONAL HEALTH ORGANIZATION; NEUTROPENIA; NON INVASIVE MEASUREMENT; NONHUMAN; PLACENTAL TRANSFER; PRACTICE GUIDELINE; PREGNANT WOMAN; PREVALENCE; PROGNOSIS; PRURITUS; SERODIAGNOSIS; SEX DIFFERENCE; SIDE EFFECT; SOUTH AND CENTRAL AMERICA; THROMBOCYTOPENIA; VERTICAL TRANSMISSION; VIRUS DIAGNOSIS; VIRUS TRANSMISSION; WEIGHT REDUCTION; BIOPSY; DISEASE TRANSMISSION; HOSPITALIZATION; LIVER; MEDICAL SOCIETY; PATHOLOGY; PATIENT SELECTION; PREDICTIVE VALUE; TREATMENT OUTCOME; VIROLOGY;

ANTIVIRAL AGENTS; BIOPSY; HEPATITIS C; HUMANS; LATIN AMERICA; LIVER; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; SEVERITY OF ILLNESS INDEX; SOCIETIES, MEDICAL; TREATMENT OUTCOME;

EID: 79955933213     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (76)

1. Houghton M. Discovery of the Hepatitis C virus. Liver Int 2009; 29(S1): 82-88.
2. Coordinación General de los Institutos Nacionales de Salud, Asociación Mexicana de Hepatología. National consensus of Hepatitis C. Ann Hepatol 2002; 1(3): 148-154.
3. Deuffic-Burban S, Poynard T, Sulkowski MS, Wong JB. Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. J Viral Hepat 2007; 14: 107-115.
4. Méndez-Sánchez N, Villa AR, Chavez-Tapia N, et al. Trends in liver disease prevalence in Mexico from 2005 to 2050 through mortality data. Ann Hepatol 2005; 4(1): 52-55.
5. Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003; 9: 331-338.
6. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management and treatment of Hepatitis C: An update. Hepatology 2009; 49(4): 1335-1374.
7. Te HS, Jensen DM. Epidemiology of hepatitis B and C viruses: A global overview. Clin Liv Dis 2010; 14: 1-21.
8. Chiquete E, Panduro A. Low prevalence of anti-hepatitis C virus antibodies in Mexico: A systematic review. Intervirology 2007; 50: 1-8.
9. Valdespino JL, Conde-González CJ, Olaiz-Fernández G, et al. Seroprevalencia de la hepatitis C en adultos de México: ¿Un problema de salud pública emergente? Salud Pública Mex 2007; 49(Suppl 3): S395-S403.
10. Pereira MLB, et al. Congresso Brasileiro de Hepatologia. 2009.
11. Secretaría de Estado de Salud Pública y Asistencia Social (SESPAS). Enfermedad Hepatitis C. Santo Domingo R.D.
12. Pérez M, Marrero E, Meléndez M, et al. Seroepidemiology of viral hepatitis, HIV and herpes simplex type 2 in the household population aged 21-64 years in Puerto Rico. BMC Infect Dis 2010; 10: 76.
13. Santana B, Guerrero F. Prevalencia de infecciones de transmisión sexual en mujeres residentes en Bateyes del ingenio Barahona. Organización Panamericana de la Salud OPS/OMS. Programa conjunto de las Naciones Unidas sobre el VIH/SIDA (ONUSIDA). 2001.
14. Hevia F, San Roman M, Aguero O. Presentaciones en eventos nacionales. Revista Médica de Costa Rica 1992; 518.
15. Hevia F, San Roman M, Aguero O. Hepatitis virales 1993.
16. Hevia F, San Roman M, Aguero O. Medicina Legal de Costa Rica 1994; 11.
17. Dávalos Moscol M. Epidemiology of hepatitis C virus in Peru and Latin America. Rev Gastroenterol Peru 2009; 29: 347-354.
18. González R, Soza A, Hernández V, et al. Incidence and prevalence of hepatitis C virus infection in Chile. Ann Hepatol. 2005; 4: 127-130.
19. Soza A, López-Lastra M. "Hepatitis C en Chile: Magnitud del problema". Rev Med Chil 2006;134: 777-788.
20. Fassio E, Schroder T y la Asociación Argentina Para, Estudio de las Enfermedades del Hígado. Conclusiones del Consenso Argentino Hepatitis C 2007. Acta Gastroenter Latinoamer 2008; 38: 56-74.
21. Esteban JI, Sauleda S, Quer J. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol 2008; 48: 148-162.
22. Murphy EL, Bryzman SM, Glynn SA, et al. Risk factors for hepatitis C virus infection in United States blood donors. NHLBI Retrovirus Epidemiology Donor Study (REDS). Hepatology 2000; 31: 756-762.
23. Ohto H, Terazawa S, Sasaki N, et al. Transmission of hepatitis C virus from mothers to infants. The Vertical Transmission of Hepatitis C Virus Collaborative Study Group. N Engl J Med 1994; 330: 744-750.
24. Zanetti AR, Tanzi E, Paccagnini S, et al. Mother-to-infant transmission of hepatitis C virus. Lombardy Study Group on Vertical HCV Transmission. Lancet 1995; 345: 289-291.
25. McIntyre PG, Tosh K, McGuire W. Caesarean section versus vaginal delivery for preventing mother to infant hepatitis C virus transmission. Cochrane Database Syst Rev 2006: CD005546.
26. Méndez-Sánchez N, Motola-Kuba D, Chavez-Tapia NC, et al. Prevalence of hepatitis C virus infection among hemodialysis patients at a tertiary-care hospital in Mexico City, Mexico. J Clin Microbiol 2004; 42: 4321-4322.
27. Pujol FH, Ponce JG, Lema MG, et al. High incidence of hepatitis C virus infection in hemodialysis patients in units with high prevalence. J Clin Microbiol 1996; 34: 1633-1636.
28. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR Recomm Rep 2001; 50: 1-52.
29. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36(Suppl): S35-S46.
30. Selzner N MI. How can we predict treatment response? In: Al Ave (Ed.). Advances in the Therapy of Liver Disease. Barcelona: Ars Medica; 1997, p. 271-277.
31. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized trial. Lancet 2001; 358 (9286): 958-965.
32. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FLJ, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347(13): 975-982.
33. Nelson DR, Davis GL, Jacobson I, Everson GT, Fried MW, Harrison SA, et al. Hepatitis C virus: A critical appraisal of approaches to therapy. Clin Gastroenterol Hepatol 2009; 7(4): 397-414.
34. McHutchinson JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype 1 infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061-1069.
35. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL- 28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
36. Awad T, Thorlund K, Hauser G, et al. Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: Systematic review of randomized trials. Hepatology 2010; 51(4): 1176-1184.
37. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon alpha 2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355.
38. Alberti A, Noventa F, Benvegnù L, Boccato S, Gatta A. Prevalence of liver disease in a population of asymptomatic individuals with hepatitis C virus infection. Ann Intern Med 2002; 137: 961-964.
39. Shakil AO, Conry-Cantilena C, Alter HJ, Hayashi P, Kleiner DE, Tedeschi V, et al. Volunteer blood donors with antibody to hepatitis C virus: Clinical, biochemical, virologic, and histologic features. Ann Intern Med 1995; 123: 330-337.
40. Puoti C, Castellacci R, Montagnese F. Hepatitis C virus carriers with persistently normal aminotransferase levels: healthy people or true patients? Dig Liver Dis 2000; 32: 634-643.
41. Puoti C, Magrini A, Stati T, Rigato P, Montagnese F, Rossi P, et al. Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels. Hepatology 1997; 26: 1393-1398.
42. Prati D, Shiffman ML, Diago M, Gane E, Rajender Reddy K, Pockros P, et al. Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis C. J Hepatol 2006; 44: 679-685.
43. Piton A, Poynard T, Imbert-Bismut F, Khalil L, Delattre J, Pelissier E, et al. Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. Hepatology 1998; 27: 1213-1219.
44. Puoti C. HCV carriers with persistently normal aminotransferase levels: Normal does not always mean healthy. J Hepatol 2003; 38: 529-532.
45. Braks RE, Ganne-Carrie N, Fontaine H, Paries J, Grando- Lemaire V, Beaugrand M et al. Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin. World J Gastroenterol 2007; 13: 5648-5653.
46. Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. Review. J Hepatol 2008; 49: 274-287.
47. Peveling-Oberhag J, Zeuzem S, Hofmann WP. Antiviral therapy of chronic hepatitis C in patients with advanced liver disease and after liver transplantation. Med Microbiol Immunol 2010; 199: 1-10
48. Gordon FD, Kwo P, Vargas HE. Treatment of hepatitis C in liver transplant recipients. Liver Transplant 2009; 15: 126-135.
49. Brown RS. Hepatitis C and liver transplantation. Nature 2005; 436: 973-978.
50. Firpi RJ, Clark V, Soldevila-Pico C, Morelli G, Cabrera R, Levy C, et al. The natural history of hepatitis C cirrhosis after liver transplantation. Liver Transplant 2009; 15: 1063-1071.
51. Everson GT, Trotter J, Forman L, Kugelmas M, Halprin A, Fey B, et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005; 42: 255-262.
52. Everson GT. Should we treat patients with chronic hepatitis C on the waiting list? J Hepatol 2005; 42: 447.
53. Roche B, Samuel D. Antiviral therapy in HCV-infected cirrhotics awaiting liver transplantation: a costly strategy for mixed virological results. J Hepatol 2009; 50: 652-654.
54. Peveling-Oberhag J, Zeuzem S, Hofmann WP. Antiviral therapy of chronic hepatitis C in patients with advanced liver disease and after liver transplantation. Med Microbiol Immunol 2010; 199: 1-10.
55. Firpi RJ, Clark V, Soldevila-Pico C, Morelli G, Cabrera R, Levy C, et al. The natural history of hepatitis C cirrhosis after liver transplantation. Liver Transplant 2009; 15: 1063-1071.
56. Sugawara Y, Makuuchi M, Matsui Y, Kishi Y, Akamatsu N, Kaneko J, et al. Preemptive therapy for hepatitis C virus after living-donor liver transplantation. Transplantation 2004; 78: 1308-1311.
57. Shergill AK, Khalili M, Straley S, Bollinger K, Roberts JP, Ascher NA, et al. Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am J Transplant 2005; 5: 118-124.
58. Chalasani N, Manzarbeitia C, Ferenci P, Vogel W, Fontana RJ, Voigt M, et al. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology 2005; 41: 289-298.
59. Reddy KR, Messinger D, Popescu M, Hadziyannis SJ. Peginterferon alpha 2a (40kDa) and rivabirin: comparable rates of sustained virological response in sub-sets of older and younger HCV genotype 1 patients. J Viral Hepat 2009; 16: 724-731.
60. Everson GT, Hoefs JC, Seeff LB et al. Impact of disease severity on outcome of antiviral therapy for chonic hepatitis C: lessons from the HALT-C trial. Hepatology 2006; 44:1675-1684.
61. Jacobson IM, González SA, Ahmed F, et al. A randomized trial of pegylated interferon alpha 2b plus ribavirin in the retreatment of chronic hepatitis C. Am J Gastroenterol 2005; 100: 2453-2462.
62. García W, Lopez J. Hepatitis C y embarazo. Rev Gastroenterol Peru 2006; 275-282.
63. Britton RC. Pregnancy and esophageal varices. Am J Surg 1982; 143(4): 412-415.
64. Cheng Y. Pregnancy in liver cirrhosis and/ or portal hypertension. Am J Obst Gynecol 1977; 128: 812.
65. Lin HH, Kao JH, Hsu HY, et al. Possible role of high titer maternal viremia in perinatal transmission of hepatitis C virus. J Infect Dis 1994; 169: 638-641.
66. Bernard O. Mother-to-infant transmission of hepatitis C. Acta Gastroenterol Belg 1998; 61: 192-194.
67. Ruiz-Extremera A, Salmeron J, Torres C, et al. Follow up of transmission of hepatitis C to babies of human immunodeficiency virus-negative women: The role of breast-feeding in transmission. Pediatr Infect Dis J 2000; 19: 511-516.
68. Bortolotti F, Resti M, Marcellini M et al. Hepatitis C virus. HCV genotypes in 373 Italian children with HCV infection: changing distribution and correlation with clinical features and outcome. Gut 2005; 54: 852-857.
69. Bortolotti F, Jorio R, Resti M, et al. Italian Observatory for HCV Infection and Hepatitis C in Children. Epidemiological profile of 806 Italian Children with hepatitis C virus infection over a 15-year period. J Hepatol 2007; 46: 783-790.
70. Guido M, Bortolotti F. Chronic viral hepatitis in children: any role for the pathologist? Gut 2008; 57: 873-877.
71. Davison SM, Mieli-Vergani G, Sira J, Kelly DA. Perinatal hepatitis C virus infection: Diagnosis and management. Arch Dis Child 2006; 91: 781-785.
72. Yu JW, Wang GQ, Sun LJ, Li XG, Li SC. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha 2a and ribavirin. J Gastroenterol Hepatol 2007; 22: 832-836.
73. Almeda-Valdés P, Cuevas-Ramos D, Aguilar-Salinas CA. Metabolic syndrome and nonalcoholic fatty liver disease. Ann Hepatol 2009; 8(1): S18-S24.
74. Camejo G, Hurt-Camejo E, Olsson U, Bondjers G. Los efectos de los ácidos grasos no esterificados sobre la matriz extracelular de las células vasculares podrían contribuir a una respuesta aterogénica. Progreso Médico 2000; 9(1): 45-53.
75. Bellentani S, Marino M. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). Ann Hepatol 2009; 8(1): S4-S8.
76. Del Campo JA, López RA, Romero-Gómez M. Insulin resistance and response to antiviral therapy in chronic hepatitis C: Mechanisms and management. Dig Dis 2010; 28(1): 285-293